Electronic Cigarette Use, Vaping
Conditions
Keywords
Vaping, Vape, Electronic cigarette, Electronic and vaping acute lung injury, EVALI
Brief summary
This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.
Detailed description
Daily vaping device users will be recruited in the Quebec City metropolitan area. Subjects will be asked to perform pulmonary function tests (spirometry, oscillometry, plethysmography, methacholine provocation) every 6 months for a 5-year follow up. Subjects will also answer a questionnaire assessing their vaping, tobacco and cannabis smoking habits, as well as their perceived respiratory symptoms. Blood draws and sputum inductions will be performed for cell counts and to measure inflammation markers.
Interventions
OTHERVaping
Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
Sponsors
Ministere de la Sante et des Services Sociaux
Laval University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older * Daily electronic cigarette user * No respiratory infection in the 4 weeks before a visit
Exclusion criteria
* Women who are pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who vape daily with impaired lung volumes. | Every 6 months for 5 years | Participants will perform plethysmography assessments to measure changes in lung volumes. Data will be expressed as a percentage of predicted values. |
| Number of participants who vape daily with impaired lung diffusion capacity. | Every 6 months for 5 years | Participants will perform diffusion capacity of the lung for carbon monoxide (DLCO) measures to assess changes in lung diffusion capacity. Data will be expressed as a percentage of predicted values. |
| Number of participants who vape daily with impaired spirometry. | Every 6 months for 5 years | Participants will perform spirometry tests measures to assess changes in forced expiratory lung volumes. Data will be expressed as a percentage of predicted values. |
| Number of participants who vape daily with airway hyperresponsiveness. | Every 6 months for 5 years | Participants will perform methacholine provocation challenge measures to assess changes in airway hyperresponsiveness. Data will be expressed as the methacholine concentration inducing a fall of 20% of forced expiratory volume in the first second assessed (PC20). |
| Number of participants who vape daily with changes in blood cell count. | Every 6 months for 5 years | Participants will perform a blood draw to assess blood cell count. Data will be expressed as a percentage of eosinophils, neutrophils, macrophages and lymphocytes of the total cell count. |
| Number of participants who vape daily with changes in sputum cell count. | Every 6 months for 5 years | Participants will perform sputum inductions to assess cell count in the sputum. Data will be expressed as a percentage of eosinophils, neutrophils, macrophages and lymphocytes of the total cell count. |
| Vaping, tobacco and cannabis smoking habits of participants. | Every 3 months for 5 years | Participants will complete questionnaires assessing their vaping habits, tobacco smoking and cannabis smoking history. |
Countries
Canada
Contacts
Primary ContactAriane Lechasseur, PhD
Backup ContactMathieu C Morissette, PhD
Outcome results
None listed